Enteropathy Clinical Trials

10 recruitingLast updated: May 13, 2026

There are 10 actively recruiting enteropathy clinical trials across 13 countries. Studies span Phase 1, Phase 2, Early Phase 1, Not Applicable. Top locations include Duarte, California, United States, New Haven, Connecticut, United States, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


Enteropathy Trials at a Glance

10 actively recruiting trials for enteropathy are listed on ClinicalTrialsFinder across 6 cities in 13 countries. The largest study group is Phase 1 with 2 trials, with the heaviest enrollment activity in Duarte, New Haven, and Boston. Lead sponsors running enteropathy studies include Institut National de la Santé Et de la Recherche Médicale, France, Dren Bio, and Children's Hospital of Philadelphia.

Browse enteropathy trials by phase

Treatments under study

About Enteropathy Clinical Trials

Looking for clinical trials for Enteropathy? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Enteropathy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Enteropathy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 2

Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)

Immune DysregulationPrimary Immune Regulatory DisorderChronic Granulomatous Disease+12 more
Paul Szabolcs25 enrolled1 locationNCT07284641
Recruiting
Phase 1Phase 2

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

Aggressive NK-cell LeukemiaLGLL - Large Granular Lymphocytic LeukemiaPrimary Cutaneous Gamma-Delta T-Cell Lymphoma+10 more
Dren Bio200 enrolled37 locationsNCT05475925
Recruiting
Not Applicable

Whole Genome Sequencing Versus Whole Exome Sequencing for Congenital Diarrhea and Enteropahty

Diarrhea InfantileEnteropathy
Children's Hospital of Fudan University180 enrolled1 locationNCT04528303
Recruiting
Phase 1

A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)

Peripheral T Cell LymphomaAnaplastic Large Cell LymphomaMycosis Fungoides+7 more
National Cancer Institute (NCI)60 enrolled1 locationNCT07055477
Recruiting
Early Phase 1

Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC

LeukemiaInborn Errors of MetabolismBone Marrow Failure Syndromes+2 more
Children's Hospital of Philadelphia100 enrolled1 locationNCT02356653
Recruiting

European Registry Study on Lymphatic Interventions

Lymphatic DisordersPlastic BronchitisProtein Losing Enteropathy+2 more
Rigshospitalet, Denmark500 enrolled1 locationNCT07131293
Recruiting

Pathogenic Study of Adult Immune Enteropathies

Inflammatory Bowel DiseasesCeliac DiseaseAutoimmune Enteropathy
Institut National de la Santé Et de la Recherche Médicale, France200 enrolled4 locationsNCT04280510
Recruiting

Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation

Autoimmune HepatitisSystemic Lupus ErythematosusHemophagocytic Lymphohistiocytoses+17 more
Institut National de la Santé Et de la Recherche Médicale, France500 enrolled1 locationNCT04902807
Recruiting

A Registry for People With T-cell Lymphoma

T-cell LymphomaNK-Cell LymphomaT-cell Prolymphocytic Leukemia+27 more
Memorial Sloan Kettering Cancer Center1,000 enrolled26 locationsNCT05978141
Recruiting

Revitalising Informal Settlements and their Environments (RISE): Assessing health, social, and environmental outcomes following water-sensitive revitalisation of informal settlements in Indonesia and Fiji

DiarrhoeaEnvironmental enteropathy
Monash University9,000 enrolled2 locationsACTRN12618000633280